Literature DB >> 16377587

Cell permeable iron chelators as potential cancer chemotherapeutic agents.

Paula M B Pahl1, Lawrence D Horwitz.   

Abstract

Iron is an essential micronutrient for the growth and function of all cells. It is, therefore, an attractive target for chemotherapeutic compounds. Numerous studies in vitro and in vivo provide evidence that iron chelators may be effective antitumor agents. Lipophilic iron chelators that are readily cell permeable and can bind intracellular iron stores may selectively kill cancer cells without damaging normal cells. In this review we discuss the role of iron in cellular processes and how these processes differ between normal and neoplastic cells. We also review the effects on normal and cancer cell growth of several lipophilic iron chelators.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16377587     DOI: 10.1080/07357900500359976

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  12 in total

Review 1.  The exochelins of pathogenic mycobacteria: unique, highly potent, lipid- and water-soluble hexadentate iron chelators with multiple potential therapeutic uses.

Authors:  Lawrence D Horwitz; Marcus A Horwitz
Journal:  Antioxid Redox Signal       Date:  2014-06-20       Impact factor: 8.401

Review 2.  Synthetic and natural iron chelators: therapeutic potential and clinical use.

Authors:  Heather C Hatcher; Ravi N Singh; Frank M Torti; Suzy V Torti
Journal:  Future Med Chem       Date:  2009-12       Impact factor: 3.808

3.  Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation.

Authors:  Michael Roth; Britta Will; Guillermo Simkin; Swathi Narayanagari; Laura Barreyro; Boris Bartholdy; Roni Tamari; Constantine S Mitsiades; Amit Verma; Ulrich Steidl
Journal:  Blood       Date:  2012-05-24       Impact factor: 22.113

4.  Distinct mechanisms of cell-kill by triapine and its terminally dimethylated derivative Dp44mT due to a loss or gain of activity of their copper(II) complexes.

Authors:  Kimiko Ishiguro; Z Ping Lin; Philip G Penketh; Krishnamurthy Shyam; Rui Zhu; Raymond P Baumann; Yong-Lian Zhu; Alan C Sartorelli; Thomas J Rutherford; Elena S Ratner
Journal:  Biochem Pharmacol       Date:  2014-08-15       Impact factor: 5.858

5.  Curcumin inhibits growth of Saccharomyces cerevisiae through iron chelation.

Authors:  Steven Minear; Allyson F O'Donnell; Anna Ballew; Guri Giaever; Corey Nislow; Tim Stearns; Martha S Cyert
Journal:  Eukaryot Cell       Date:  2011-09-09

Review 6.  The neglected significance of "antioxidative stress".

Authors:  B Poljsak; I Milisav
Journal:  Oxid Med Cell Longev       Date:  2012-05-08       Impact factor: 6.543

7.  In vitro growth inhibition of bloodstream forms of Trypanosoma brucei and Trypanosoma congolense by iron chelators.

Authors:  Karin Merschjohann; Dietmar Steverding
Journal:  Kinetoplastid Biol Dis       Date:  2006-08-16

8.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

9.  Initial in vivo testing of TPO-receptor agonist eltrombopag in osteosarcoma patient-derived xenograft models by the pediatric preclinical testing consortium.

Authors:  Grace Nevil; Michael Roth; Jonathan Gill; Wendong Zhang; Beverly Teicher; Stephen W Erickson; Gregory Gatto; Malcom Smith; E Anders Kolb; Richard Gorlick
Journal:  Pediatr Hematol Oncol       Date:  2020-08-17       Impact factor: 1.969

10.  The cytotoxicity of benzaldehyde nitrogen mustard-2-pyridine carboxylic acid hydrazone being involved in topoisomerase IIα inhibition.

Authors:  Yun Fu; Sufeng Zhou; Youxun Liu; Yingli Yang; Xingzhi Sun; Changzheng Li
Journal:  Biomed Res Int       Date:  2014-06-05       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.